Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lorundrostat added to background antihypertensive therapy in uncontrolled and resistant hypertension
NL-OMON60860Phase 3Completed
- Sponsor
- Mineralys Therapeutics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and resistant hypertension (RH) comparing Lorundrostat with Placebo (2 arms). Primary endpoint: Change from baseline in automated office systolic blood pressure at Week 6. Started May 2024; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NL-OMON60860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60860.